ProQR Therapeutics N.V. (PRQR)
2.27
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
2.26
-0.44%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.13 |
| Market Cap | 234.27M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.31 |
| PE Ratio (ttm) | -7.32 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3 |
| Volume | 334,106 |
| Avg. Volume (20D) | 1,626,654 |
| Open | 2.30 |
| Previous Close | 2.27 |
| Day's Range | 2.19 - 2.34 |
| 52-Week Range | 1.61 - 4.62 |
| Beta | undefined |
About PRQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2014
Employees 156
Stock Exchange NASDAQ
Ticker Symbol PRQR
Website https://www.proqr.com
Analyst Forecast
According to 5 analyst ratings, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 252.42% from the latest price.
Buy 80.00%
Hold 20.00%
Sell 0.00%
Next Earnings Release
ProQR Therapeutics N.V. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of $6.97M, reflecting a 97.17% YoY growth and earnings per share of -0.15, making a 87.50% increase YoY.
Analysts project revenue of $6.97M, reflecting a 97.17% YoY growth and earnings per share of -0.15, making a 87.50% increase YoY.
2 months ago ·
Source
+5.6%
ProQR Therapeutics shares are trading higher afer ...
Unlock content with
Pro Subscription
5 months ago ·
Source
+12.57%
Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
